title: Dopamine agonists diminish value sensitivity of the orbitofrontal cortex: a trigger for pathological gambling in Parkinson's disease?
abstract: The neurobehavioral underpinnings of pathological gambling are not well understood. Insight might be gained by understanding pharmacological effects on the reward system in patients with Parkinson's disease (PD). Treatment with dopamine agonists (DAs) has been associated with pathological gambling in PD patients. However, how DAs are involved in the development of this form of addiction is unknown. We tested the hypothesis that tonic stimulation of dopamine receptors specifically desensitizes the dopaminergic reward system by preventing decreases in dopaminergic transmission that occurs with negative feedback. Using functional magnetic resonance imaging, we studied PD patients during three sessions of a probabilistic reward task in random order: off medication, after levodopa (LD) treatment, and after an equivalent dose of DA (pramipexole). For each trial, a reward prediction error value was computed using outcome, stake, and probability. Pramipexole specifically changed activity of the orbitofrontal cortex (OFC) in two ways that were both associated with increased risk taking in an out-of-magnet task. Outcome-induced activations were generally higher with pramipexole compared with LD or off medication. In addition, only pramipexole greatly diminished trial-by-trial correlation with reward prediction error values. Further analysis yielded that this resulted mainly from impaired deactivation in trials with negative errors in reward prediction. We propose that DAs prevent pauses in dopamine transmission and thereby impair the negative reinforcing effect of losing. Our findings raise the question of whether pathological gambling may in part stem from an impaired capacity of the OFC to guide behavior when facing negative consequences.
authors.affiliation: Division of Brain, Imaging and Behaviour-Systems Neuroscience, BIB-SN, Toronto Western Research Institute, University of Toronto, Toronto, ON, Canada.
authors.forename: Thilo
authors.initials: T
authors.lastname: van Eimeren
authors.forename: Bénédicte
authors.initials: B
authors.lastname: Ballanger
authors.forename: Giovanna
authors.initials: G
authors.lastname: Pellecchia
authors.forename: Janis M
authors.initials: JM
authors.lastname: Miyasaki
authors.forename: Anthony E
authors.initials: AE
authors.lastname: Lang
authors.forename: Antonio P
authors.initials: AP
authors.lastname: Strafella
mesh_terms: D052160:Benzothiazoles / Q000494:pharmacology / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000494:pharmacology* / Q000627:therapeutic use; D005625:Frontal Lobe / Q000187:drug effects* / Q000503:physiopathology; D005715:Gambling / Q000523:psychology*; D006801:Humans; D007980:Levodopa / Q000494:pharmacology / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology / Q000523:psychology*; D000077487:Pramipexole; D011597:Psychomotor Performance / Q000187:drug effects / Q000502:physiology; D012201:Reward; D012309:Risk-Taking
chemical_list: D052160:Benzothiazoles; D018491:Dopamine Agonists; D007980:Levodopa; D000077487:Pramipexole